An observational study released by The Wellness Company and the McCullough Foundation says 84% of 197 cancer patients experienced a clinical benefit after receiving a compounded ivermectin‑mebendazole regimen. The researchers, led by Dr. Peter McCullough, presented the findings in a peer‑reviewed oncology journal and called for more rigorous trials. While the data are intriguing, experts warn that the lack of a control group and vague benefit metrics limit any firm conclusions.

84% Clinical Benefit Ratio in 197 Patients

The study cites an 84% Clinical Benefit Ratio among 197 participants who were prescribed 25 mg of ivermectin and 250 mg of mebendazole daily.. According to the press release, this metric aggregates responses across multiple cancer types,though the exact criteria for “benefit” were not disclosed. Dr. Peter McCullough, Chief Scientific Officer of The Wellness Company, highlighted the figure as evidence that inexpensive,widely available drugs could address the toxicity and cost issues of conventional oncology treatments.

86.9% Prescription Completion Suggests Tolerability

The authors note that 86.9% of patients completed their initial prescription, which they interpret as a sign of tolerability.. Nicolas Hulscher of the McCullough Foundation emphasized that real‑world observational data can reflect practical treatment applications, especially when patients are able to adhere to a high‑dose regimen without major adverse events.

Patient Testimonials Highlight PET Scan Remission

Among the anecdotes shared , a stage‑4 metastatic breast cancer patient reportedly showed no live cancer on a PET scan after treatment, and a uterine‑lung cancer patient claimed significant nodule reduction within two weeks. The press release includes these stories to illustrate potential outcomes, but the article notes that the testimonials lack detailed clinical verification and should be treated cautiously.

Conflict of Interest: Wellness Company as Sponsor and Vendor

The Wellness Company is both the study sponsor and the sole U.S. provider of the compounded high‑dose tablets, marketing them as a “parasite cleanse” with alleged Nobel‑prize‑backed efficacy. This dual role raises concerns about bias, especially since the company also offers promotional discounts to U.S. residents. Independent replication will be essential to determine whether observed benefits stem from the drug combination or from confounding factors .

Key Uncertainties: Lack of Control Group and Benefit Definition

Critics point out that the observational design cannot establish causality, and the study’s small sample size limits statistical power. The specific criteria used to calculate the 84% Clinical Benefit Ratio were not detailed, leaving readers uncertain about what outcomes were counted. As the authors themselves acknowledge, randomized controlled trials are needed before the regimen can be considered a viable alternative to chemotherapy , radiation, or targeted agents.